Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


Assessing the toxicity of bispecific antibodies

The on-target off-tumour toxicities of T-cell-engaging bispecific antibodies in patients can be captured in intestinal organoids derived from the patients’ biopsied tissue and supplemented with immune cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Organoid models generated from healthy and malignant intestinal tissues and co-cultured with allogeneic T cells for the study of the on-target off-tumour toxicities of TCBs.


  1. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Nat Biotechnol. 32, 40–51 (2014).

    Article  CAS  PubMed  Google Scholar 

  2. Clevers, H. Cell 165, 1586–1597 (2016).

    Article  CAS  PubMed  Google Scholar 

  3. Schnalzger, T. E. et al. EMBO J. 38, e100928 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gonzalez-Exposito, R. et al. J. Immunother. Cancer 7, 101 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Harter, M. F. et al. Nat. Biomed. Eng. (2023).

    Article  PubMed  Google Scholar 

  6. Xu, H. et al. Exp. Hematol. Oncol. 7, 30 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Votanopoulos, K. I. et al. Ann. Surg. Oncol. 27, 1956–1967 (2020).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Marco Gerlinger.

Ethics declarations

Competing interests

M.G. receives institutional research funding from Bristol Myers Squibb, Merck KG and Roche, speaker fees from Bristol Myers Squibb and Merck KG, and expert advisory fees from Merck Sharp and Dohme and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buzzetti, M., Gerlinger, M. Assessing the toxicity of bispecific antibodies. Nat. Biomed. Eng 8, 339–340 (2024).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research